SCHEMBL3385876

SCHEMBL3385876

Cc1ccc(C(CCO)NC(=O)C2SCCN2S(=O)(=O)c2ccc(-c3ccccc3)cc2)c(C)c1

nearest known ligand 0.53

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PTGFR P43088 1/20 0.53
HSD11B1 P28845 4/20 0.42
MMP9 P14780 3/20 0.38
MMP2 P08253 2/20 0.38
ALDH1A1 P00352 3/20 0.37
LMNA P02545 2/20 0.37
TSHR P16473 1/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MMP1 P03956 1/20 0.36
MMP3 P08254 1/20 0.36
ADAM17 P78536 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3384306 0.91 PTGFR (0.56) PTGFRHSD11B1MMP9MMP2ALDH1A1
SCHEMBL3384077 0.88 PTGFR (0.64) PTGFRHSD11B1MMP9MMP2ALDH1A1
SCHEMBL3383657 0.85 PTGFR (0.59) PTGFRHSD11B1MMP9MMP2MMP1
SCHEMBL3383620 0.85 PTGFR (0.64) PTGFRHSD11B1MMP9MMP2ALDH1A1
SCHEMBL3382557 0.85 PTGFR (0.64) PTGFRHSD11B1MMP9MMP2ALDH1A1
SCHEMBL3386103 0.85 PTGFR (0.64) PTGFRHSD11B1MMP9MMP2ALDH1A1
SCHEMBL3382579 0.85 PTGFR (0.64) PTGFRHSD11B1MMP9MMP2ALDH1A1
SCHEMBL3382653 0.85 PTGFR (0.64) PTGFRHSD11B1MMP9MMP2ALDH1A1
SCHEMBL3383011 0.85 PTGFR (0.58) PTGFRHSD11B1MMP9MMP2ALDH1A1
SCHEMBL7045217 0.84 PTGFR (0.58) PTGFRHSD11B1MMP9MMP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240024294-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF PRETERM LABOR XOMA (US) LLC 2024-01-25 US disclosed
US-20230372306-A1 COMPOSITIONS AND METHODS FOR DELAYING THE INCIDENCE OF LABOR XOMA (US) LLC 2023-11-23 US disclosed
US-11534428-B1 Compositions and methods for delaying the incidence of labor XOMA (US) LLC (US) 2022-12-27 US disclosed
US-8415480-B2 Thiazolidine carboxamide derivatives as modulators of the prostaglandin F receptor MERCK SERONO SA (CH) 2013-04-09 US disclosed
US-8415480-B2 Thiazolidine carboxamide derivatives as modulators of the prostaglandin F receptor MERCK SERONO SA (CH) 2013-04-09 US disclosed
US-8415480-B2 Thiazolidine carboxamide derivatives as modulators of the prostaglandin F receptor MERCK SERONO SA (CH) 2013-04-09 US disclosed
EP-1487442-B1 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR MERCK SERONO SA (CH) 2010-12-01 EP disclosed
EP-1487442-B1 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR MERCK SERONO SA (CH) 2010-12-01 EP disclosed
US-20090215749-A9 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR LABORATOIRES SERONO S.A. (CH) 2009-08-27 US disclosed
US-20090215749-A9 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR LABORATOIRES SERONO S.A. (CH) 2009-08-27 US disclosed
US-20090215749-A9 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR LABORATOIRES SERONO S.A. (CH) 2009-08-27 US disclosed
US-20080255094-A1 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR LABORATOIRES SERONO S.A. (CH) 2008-10-16 US disclosed
US-20080255094-A1 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR LABORATOIRES SERONO S.A. (CH) 2008-10-16 US disclosed
US-20080255094-A1 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR LABORATOIRES SERONO S.A. (CH) 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230372306-A1 COMPOSITIONS AND METHODS FOR DELAYING THE INCIDENCE OF LABOR PGF, TRPV2, TRPV3 PTGFR 9/4885HSD11B1 2075/4885MMP9 3917/4885
US-20240024294-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF PRETERM LABOR PGF, PTGS1, PTGIR PTGFR 7/4885HSD11B1 2481/4885MMP9 2784/4885
US-20090215749-A9 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR PTGER4, PTGER2, PTGER1 PTGFR 9/4885HSD11B1 2095/4885MMP9 4351/4885
US-11534428-B1 Compositions and methods for delaying the incidence of labor PGF, TRPV2, TRPV3 PTGFR 9/4885HSD11B1 2075/4885MMP9 3917/4885
US-20080255094-A1 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR PTGER4, PTGER2, PTGER1 PTGFR 9/4885HSD11B1 2095/4885MMP9 4351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.